Tango Therapeutics (TNGX) Net Cash Flow (2020 - 2026)

Tango Therapeutics' Net Cash Flow history runs 7 years deep, the most recent figure standing at $45.1 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 506.57% year-over-year to $45.1 million; the TTM figure through Mar 2026 stood at $99.0 million (up 3723.87% YoY), while the FY2025 annual figure was $42.7 million, up 1767.58% from the prior year.
• Net Cash Flow was $45.1 million for Q1 2026 at Tango Therapeutics, down from $53.9 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $53.9 million in Q4 2025 to a low of -$41.1 million in Q1 2022.
• Historically, Net Cash Flow has averaged $879000.0 across 5 years, with a median of -$3.3 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Net Cash Flow sank 209.93% in 2022, then jumped 1105.18% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$40.3 million in 2022, then jumped by 119.46% to $7.9 million in 2023, then jumped by 108.63% to $16.4 million in 2024, then surged by 229.27% to $53.9 million in 2025, then retreated by 16.35% to $45.1 million in 2026.
• The last three Net Cash Flow figures came in at $45.1 million (Q1 2026), $53.9 million (Q4 2025), and $19.1 million (Q3 2025), per Business Quant data.